FDA https://www.fda.gov has announced the global launch of “CURE-ID” an internet-based repository, which is a collaboration between FDA and NIH’s “National Center for Advancing Translational Sciences” (NCATS) https://ncats.nih.gov.
The repository enables the global clinical community to report their experiences treating difficult-to-treat infectious diseases by using novel means of using existing FDA approved drugs. An app can relay information through a website, a smartphone, or through other mobile devices.
The platform enables the crowdsourcing of medical information from healthcare providers to guide potentially life-saving interventions and make it possible to develop new drugs for neglected diseases.
The “CURE ID” app focuses on drugs for infectious diseases lacking adequate treatments, including neglected tropical diseases plus drugs for emerging infectious threats and infections caused by antimicrobial-resistant organisms.
The repository captures clinical outcomes for drugs used for new indications in new populations, in new doses, or in new combinations. The systematic collection of real-world experience in the app will help identify drug candidates for additional study, encourage further drug development, and may serve as a resource for practitioners making individual patient treatment decisions in the absence of established safe and effective options.
“When healthcare professionals directly input their clinical cases into the app, “CURE ID” allows real-world experiences to be organized and analyzed much faster, making it easier to spot promising new uses for existing drugs. Our hope is that the app will serve as a connector among major treatment centers, academics, private practitioners, government facilities, and other healthcare professions around the world said, Amy Abernethy MD, PhD, and FDA Principal Deputy Commissioner.
Go to https://drugs/science-and-research-drugs/cure-id-app-lets-clinicians-report-novel-uses-existing-drugs for more information on CURE ID.